1558. Commensal Neisseria Species as a Cause of Disease in Patients Taking Eculizumab
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

1558. Commensal Neisseria Species as a Cause of Disease in Patients Taking Eculizumab

Filetype[PDF-830.63 KB]


English
Details Supporting Files You May Also Like

Details:

  • Alternative Title:
    Open Forum Infect Dis
  • Personal Author:
  • Conference Authors:
    IDWeek (2018 October 3-7 : San Franciso, CA)
  • Description:
    Background

    Non-meningococcal and nongonococcal Neisseria spp. are usually commensal and rarely cause invasive disease in humans. Eculizumab, a terminal complement inhibitor, increases susceptibility to meningococcal disease, but data on atypical Neisseria spp. disease in persons receiving eculizumab are lacking. This case series describes postmarketing reports of disease by commensal Neisseria spp. in patients receiving eculizumab.

    Methods

    The FDA Adverse Event Reporting System (FAERS) database and the medical literature were searched for cases of disease by any nonmeningococcal and nongonococcal Neisseria spp. in patients receiving eculizumab. Included cases had a diagnosis of disease by any atypical Neisseria spp. with onset on or before January 31, 2018 and ≥1 dose of eculizumab in the 3 months prior to disease.

    Results

    The search identified seven FAERS cases, including one case also reported in the literature. Patient ages ranged from 4 to 38 years. Five patients had positive blood cultures, of which three had an indwelling catheter for vascular access (n = 2, N. sicca/subflava) or hemodialysis (n = 1, N. cinerea). Two patients with bacteremia had N. cinerea septic shock with possible cholecystitis, and N. mucosa sepsis with concurrent Streptococcus bacteremia after gastroenteritis. The remaining two cases in the series included one with N. sicca bacterial peritonitis associated with a peritoneal dialysis catheter (negative blood cultures, other cultures not specified), and one with a diagnosis of N. flavescens sepsis while neutropenic (specimen source not specified). All seven patients were hospitalized and three had sepsis or septic shock. All cases resolved with antibiotics and supportive care.

    Conclusion

    We identified seven cases of serious disease caused by atypical Neisseria spp. among eculizumab recipients. Since these organisms are typical inhabitants of the oropharynx and urogenital tract and are not skin flora, the source of disease was unclear. Our data suggest that eculizumab may confer increased risk for disease by usually commensal Neisseria spp. Healthcare professionals are encouraged to treat all Neisseria spp. isolated from sterile sites as pathogenic, and not as contaminants, in patients receiving eculizumab.

    Disclosures

    All authors: No reported disclosures.

  • Subjects:
  • Source:
    Open Forum Infect Dis. 2018; 5(Suppl 1):S484-S485.
  • Pubmed Central ID:
    PMC6252520
  • Document Type:
    Journal Article
  • Genre:
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

You May Also Like

Checkout today's featured content at stacks.cdc.gov